Search Results - "Bergeron, Meghan"

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation by Fathi, Amir T., Blonquist, Traci M., Hernandez, Daniela, Amrein, Philip C., Ballen, Karen K., McMasters, Malgorzata, Avigan, David E., Joyce, Robin, Logan, Emma K., Hobbs, Gabriela, Brunner, Andrew M., Joseph, Christelle, Perry, Ashley M., Burke, Meghan, Behnan, Tanya, Foster, Julia, Bergeron, Meghan K., Moran, Jenna A., Ramos, Aura Y., Som, Tina T., Rae, Jessica, Fishman, Kaitlyn M., McGregor, Kristin L., Connolly, Christine, Neuberg, Donna S., Levis, Mark J.

“…BACKGROUND Cabozantinib, a tyrosine kinase inhibitor of FMS‐like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is…”
Get full text

A phase 1 study of the antibody‐drug conjugate brentuximab vedotin with re‐induction chemotherapy in patients with CD30‐expressing relapsed/refractory acute myeloid leukemia by Narayan, Rupa, Blonquist, Traci M., Emadi, Ashkan, Hasserjian, Robert P., Burke, Meghan, Lescinskas, Christopher, Neuberg, Donna S., Brunner, Andrew M., Hobbs, Gabriela, Hock, Hanno, McAfee, Steven L., Chen, Yi‐Bin, Attar, Eyal, Graubert, Timothy A., Bertoli, Christina, Moran, Jenna A., Bergeron, Meghan K., Foster, Julia E., Ramos, Aura Y., Som, Tina T., Vartanian, Megan K., Story, Jennifer L., McGregor, Kristin, Macrae, Molly, Behnan, Tanya, Wey, Margaret C., Rae, Jessica, Preffer, Frederic I., Lesho, Patricia, Duong, Vu H., Mann, Mason L., Ballen, Karen K., Connolly, Christine, Amrein, Philip C., Fathi, Amir T.

“…Background Outcomes for patients with relapsed/refractory acute myeloid leukemia (R/R AML) remain poor. Novel therapies specifically targeting AML are of high…”
Get full text

Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy by Venkataraman, Vinayak, Casey, Keagan S., Onozato, Maristela, Cin, Paola Dal, Nardi, Valentina, Amrein, Philip C., Bergeron, Meghan K., Brunner, Andrew M., Fathi, Amir T., Foster, Julia E., Moran, Jenna, Graubert, Timothy A., Hock, Hanno, Hunnewell, Chrisa, Frigault, Matthew J., McAfee, Steven, Hobbs, Gabriela S.

Get full text

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia by Fathi, Amir T, Wander, Seth A, Blonquist, Traci M, Brunner, Andrew M, Amrein, Philip C, Supko, Jeffrey, Hermance, Nicole M, Manning, Amity L, Sadrzadeh, Hossein, Ballen, Karen K, Attar, Eyal C, Graubert, Timothy A, Hobbs, Gabriela, Joseph, Christelle, Perry, Ashley M, Burke, Meghan, Silver, Regina, Foster, Julia, Bergeron, Meghan, Ramos, Aura Y, Som, Tina T, Fishman, Kaitlyn M, McGregor, Kristin L, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin

“…Aberrant expression of aurora kinase A is implicated in the genesis of various neoplasms, including acute myeloid leukemia. Alisertib, an aurora A kinase…”
Get full text

A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies by How, Joan, Ren, Siyang, Lombardi‐Story, Jennifer, Bergeron, Meghan, Foster, Julia, Amrein, Phillip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno, Khachatryan, Anna, Kikuchi, Hiroto, Ng, Mei Rosa, Moran, Jenna, Narayan, Rupa, Neuberg, Donna, Ramos, Aura, Som, Tina, Vartanian, Meghan, Chen, Yi‐Bin, Duda, Dan G., Hobbs, Gabriela S.

“…We conducted a single‐center, open‐label, dose escalation, and expansion phase I trial of the antiangiogenic multikinase inhibitor regorafenib in patients with…”
Get full text

Long: molecular tracking of CML with bilineal inv lymphoid blast crisis and durable response to CD19-directed CAR-T therapy by Venkataraman, Vinayak, Casey, Keagan S, Onozato, Maristela, Cin, Paola Dal, Nardi, Valentina, Amrein, Philip C, Bergeron, Meghan K

Get full text

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey G, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven, Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

Get full text

Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML) by Fathi, Amir T., Perl, Alexander E., Levis, Mark, Smith, Catherine C., Brunner, Andrew M., Takahashi, Koichi, Amrein, Philip C., Hock, Hanno R., Hobbs, Gabriela S., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Daver, Naval, DiNardo, Courtney D.

“…Characterization of pathogenic alterations in acute myeloid leukemia (AML) has led to development of promising targeted therapies, including FLT3 (FLT3i) and…”
Get full text

Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia in older adults by Amrein, Philip, Ballen, Karen, Stevenson, Kristen, Brunner, Andrew, Hobbs, Gabriela, Hock, Hanno, McAfee, Steven, Moran, Jenna, Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGreggor, Kristin, Macrea, Molly, Burke, Meghan, Behnam, Tanya, Som, Tina, Ramos, Aura, Vartanian, Megan, Lombardi Story, Jennifer, Connolly, Christine, Blonquist, Traci, Neuberg, Donna, Fathi, Amir

“…We sought to assess the safety of adding ixazomib, an oral proteasome inhibitor, to a multi-agent treatment regimen for older adults with acute lymphoblastic…”
Get full text

Phase I Study of Ixazomib Added to Chemotherapy in the Treatment of Acute Lymphoblastic Leukemia in Older Adults by Amrein, Philip C., Ballen, Karen K., Stevenson, Kristen E., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Graubert, Timothy A., Neuberg, Donna S., Fathi, Amir T.

“…Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia…”
Get full text

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Fell, Geoffrey, Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno R., McAfee, Steven L., Narayan, Rupa, Moran, Jenna A., Bergeron, Meghan, Foster, Julia E., Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S., Fathi, Amir T.

“…Introduction: Outcomes for acute myeloid leukemia (AML) among older patients has remained largely unchanged for decades. Long-term survival for patients aged…”
Get full text

A Phase 1 Trial of Regorafenib in Advanced Myeloid Malignancies by How, Chi-Joan, Ren, Siyang, Lombardi Story, Jennifer, Bergeron, Meghan, Foster, Julia E., Amrein, Philip C., Brunner, Andrew M., Fathi, Amir T., Hock, Hanno R., Moran, Jenna A., Narayan, Rupa, Neuberg, Donna S., Ramos, Aura Y., Som, Tina T., Vartanian, Megan, Chen, Yi-Bin, Hobbs, Gabriela S.

“…Angiogenesis is increasingly known to play a role in pathogenesis of hematologic malignancies, including myeloid neoplasms. Regorafenib is a multikinase…”
Get full text

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults by Amrein, Philip C., Ballen, Karen K., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Fathi, Amir T.

“…Introduction: While progress has been made in the treatment of childhood leukemia, the outlook for patients >60 years of age with acute lymphoblastic leukemia…”
Get full text

Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults by Amrein, Philip C., Attar, Eyal C., Blonquist, Traci M., Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Neuberg, Donna S, Fathi, Amir T.

“…Introduction: Treatment of acute myeloid leukemia (AML) has remained largely unchanged for several decades despite the emergence of new agents. Long-term…”
Get full text

Phase I Study of the Antibody-Drug Conjugate Brentuximab Vedotin Combined with Re-Induction Chemotherapy in Patients with CD30-Expressing Relapsed/Refractory Acute Myeloid Leukemia by Fathi, Amir T., Blonquist, Traci M., Emadi, Ashkan, Brunner, Andrew M., Hobbs, Gabriela S., Hock, Hanno, McAfee, Steven L, Hasserjian, Robert P., Preffer, Frederic I., Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Lombardi Story, Jennifer, Lesho, Patricia, Duong, Vu H., Mann, Mason, Lescinskas, Christopher, Connolly, Christine, Neuberg, Donna S, Ballen, Karen K., Amrein, Philip C.

“…Background: Brentuximab vedotin (BV) is an antibody-drug conjugate (ADC) consisting of an antibody specific for human CD30, an anti-microtubule agent…”
Get full text

Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia by Brunner, Andrew M., Blonquist, Traci M., DeAngelo, Daniel J., McMasters, Malgorzata, Winer, Eric S., Hobbs, Gabriela S., Amrein, Philip C., Hock, Hanno, Steensma, David P., Garcia, Jacqueline S., Luskin, Marlise R., Stone, Richard M., Ballen, Karen K., Rosenblatt, Jacalyn, Avigan, David E., McAfee, Steven L, Moran, Jenna A., Bergeron, Meghan, Foster, Julia, Bertoli, Christina, McGregor, Kristin, Fishman, Kaitlyn, Macrae, Molly, Burke, Meghan, Behnan, Tanya T., Som, Tina T., Ramos, Aura Y., Vartanian, Megan K., Nelson, Nicole, Logan, Emma, Lombardi Story, Jennifer, Connolly, Christine, Neuberg, Donna S, Chen, Yi-Bin, Graubert, Timothy A., Fathi, Amir T.

“…▪ Background: Aurora kinases play essential roles in regulating cell division, and increased expression has been noted in myelodysplastic syndromes (MDS) and…”
Get full text

Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy by Venkataraman, Vinayak, Casey, Keagan S, Onozato, Maristela, Cin, Paola Dal, Nardi, Valentina, Amrein, Philip C, Bergeron, Meghan K, Brunner, Andrew M, Fathi, Amir T, Foster, Julia E, Moran, Jenna, Graubert, Timothy A, Hock, Hanno, Hunnewell, Chrisa, Frigault, Matthew J, McAfee, Steven, Hobbs, Gabriela S

Get full text